SCHEMBL25633302

SCHEMBL25633302

COC(=O)Cn1nc(N(C)C)n2c(cc3ccccc32)c1=O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.50
NPC1 O15118 1/20 0.47
MAPT P10636 2/20 0.46
TP53 P04637 2/20 0.46
ALDH1A1 P00352 3/20 0.45
LMNA P02545 2/20 0.45
HPGD P15428 2/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
ALOX15 P16050 1/20 0.45
MCL1 Q07820 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KDM4E B2RXH2 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TSHR P16473 1/20 0.45
RXFP1 Q9HBX9 2/20 0.43
NLRP3 Q96P20 2/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30279649 1.00 THRB (0.50) THRBNPC1MAPTTP53ALDH1A1
SCHEMBL25633347 0.88 THRB (0.51) THRBNPC1MAPTTP53ALDH1A1
SCHEMBL30279647 0.86 TP53 (0.47) THRBMAPTTP53ALDH1A1LMNA
SCHEMBL25633321 0.86 TP53 (0.47) THRBMAPTTP53ALDH1A1LMNA
SCHEMBL25633317 0.84 THRB (0.50) THRBNPC1MAPTTP53ALDH1A1
SCHEMBL30279659 0.84 THRB (0.50) THRBNPC1MAPTTP53ALDH1A1
SCHEMBL23975546 0.84 THRB (0.54) THRBNPC1MAPTTP53ALDH1A1
SCHEMBL30279639 0.84 THRB (0.52) THRBNPC1MAPTTP53ALDH1A1
SCHEMBL30279652 0.84 THRB (0.54) THRBNPC1MAPTTP53ALDH1A1
SCHEMBL25633303 0.84 THRB (0.52) THRBNPC1MAPTTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183249-A1 NEW TRIAZINOINDOLE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-15 US disclosed
US-20230183249-A1 NEW TRIAZINOINDOLE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183249-A1 NEW TRIAZINOINDOLE COMPOUNDS NLRP3, NLRP1, PYCARD THRB 277/4885NPC1 364/4885MAPT 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.